This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Daniel J. Morris, MD
H. Lee Moffitt Cancer Center and Research Institute University of South Florida Tampa

JAMA. 1990;264(3):334.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Much has been written about the ethics of marketing practices and trends of the pharmaceutical industry. Another event related to this subject that I would like to call to my colleagues' attention is a strategy recently practiced by the brokerage industry.

A stockbroker called and indicated to my secretary that he was calling about erythropoietin. He, of course, did not tell my secretary that he was a broker, and she, of course, quite naturally thought he was providing prescribing and pharmaceutical information rather than soliciting a stock account with me.

The stockbroker, from the Tampa, Fla, office of Shearson Lehman Hutton, admitted that his strategy was to solicit accounts specifically by calling physicians' offices to discuss the stock market profit potential of biotechnology stocks.

I advised the stockbroker that, as an oncologist who prescribes the products he was discussing, I could not actively participate in specific issues, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?